What You Should Know:
- Quest Diagnostics announced that it has completed its $450M acquisition of Haystack Oncology.
- Haystack Oncology has developed a highly sensitive minimal-residual disease (MRD) testing technology, based on circulating tumor DNA (ctDNA), to aid in the early detection of residual or recurring cancer and better inform therapy decisions.
- Acquired back in April, the acquisition will leverage Quest’s expertise and scale in oncology, genomics and pathology. Quest expects to incorporate this MRD technology into the development of new blood-based clinical lab services for solid tumor cancers available beginning in 2024.
